
Tivdak, which was approved as a cervical cancer treatment in the US last year, is the first drug that Danish biotech company Genmab has chosen to sell and market itself.
Although Tivdak’s indication makes it only relevant for a few thousand patients, CEO of Genmab Jan van de Winkel doesn’t shy away from its importance.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app